TW202214261A - 硼酸類化合物 - Google Patents

硼酸類化合物 Download PDF

Info

Publication number
TW202214261A
TW202214261A TW110130943A TW110130943A TW202214261A TW 202214261 A TW202214261 A TW 202214261A TW 110130943 A TW110130943 A TW 110130943A TW 110130943 A TW110130943 A TW 110130943A TW 202214261 A TW202214261 A TW 202214261A
Authority
TW
Taiwan
Prior art keywords
compound
mmol
added
mixture
stirred
Prior art date
Application number
TW110130943A
Other languages
English (en)
Chinese (zh)
Inventor
東輝 秦
Original Assignee
大陸商輝諾生物醫藥科技(杭州)有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大陸商輝諾生物醫藥科技(杭州)有限公司 filed Critical 大陸商輝諾生物醫藥科技(杭州)有限公司
Publication of TW202214261A publication Critical patent/TW202214261A/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/025Boronic and borinic acid compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/04Esters of boric acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW110130943A 2020-08-20 2021-08-20 硼酸類化合物 TW202214261A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN202010845001.1 2020-08-20
CN202010845001 2020-08-20
CN202110373982.9 2021-04-07
CN202110373982 2021-04-07

Publications (1)

Publication Number Publication Date
TW202214261A true TW202214261A (zh) 2022-04-16

Family

ID=80322587

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110130943A TW202214261A (zh) 2020-08-20 2021-08-20 硼酸類化合物

Country Status (7)

Country Link
US (1) US12590108B2 (https=)
EP (1) EP4201942A4 (https=)
JP (1) JP2023538645A (https=)
KR (1) KR20230104117A (https=)
CN (1) CN116615431A (https=)
TW (1) TW202214261A (https=)
WO (1) WO2022037680A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023155869A1 (zh) * 2022-02-18 2023-08-24 辉诺生物医药科技(杭州)有限公司 新的硼酸类化合物的晶型及其制备方法
WO2025228222A1 (zh) * 2024-04-30 2025-11-06 珠海联邦制药股份有限公司 硼酸类β-内酰胺酶抑制剂及其应用
WO2026067428A1 (zh) * 2024-09-30 2026-04-02 科睿迪(南京)医药科技有限公司 硼酸衍生物及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100120715A1 (en) * 2007-11-13 2010-05-13 Burns Christopher J Beta-lactamase inhibitors
US20100292185A1 (en) 2009-05-12 2010-11-18 Burns Christopher J Beta-lactamase inhibitors
US9012491B2 (en) * 2011-08-31 2015-04-21 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
CN105026407B (zh) * 2012-12-07 2017-09-08 维纳拓尔斯制药公司 β‑内酰胺酶抑制剂
US20180051041A1 (en) * 2015-03-17 2018-02-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
ES2894251T3 (es) * 2016-06-30 2022-02-14 Qpex Biopharma Inc Derivados de ácido borónico y usos terapéuticos de los mismos

Also Published As

Publication number Publication date
WO2022037680A1 (zh) 2022-02-24
US12590108B2 (en) 2026-03-31
KR20230104117A (ko) 2023-07-07
CN116615431A (zh) 2023-08-18
US20240294554A1 (en) 2024-09-05
EP4201942A1 (en) 2023-06-28
JP2023538645A (ja) 2023-09-08
EP4201942A4 (en) 2024-08-21

Similar Documents

Publication Publication Date Title
TWI761961B (zh) 稠合吡啶酮類化合物及其製備方法和應用
TW202304911A (zh) 吡啶醯胺類化合物
TW202214261A (zh) 硼酸類化合物
JP2021523875A (ja) Fgfr阻害剤としてのピラジン−2(1h)−オン系化合物
CN104994844A (zh) 硼酸衍生物及其治疗用途
TW200946528A (en) Piperidine derivatives
CN114846008B (zh) 具有果糖激酶(khk)抑制作用的嘧啶类化合物
TW202128699A (zh) 治療性化合物
WO2022166721A1 (zh) 含1,4-氧杂氮杂环庚烷的并环类衍生物
CA3101373A1 (en) 2,3-dihydro-1h-pyrrolizine-7-formamide derivative and application thereof
CN112955453B (zh) 作为选择性Trk抑制剂的吡唑并嘧啶衍生物
JP2021514997A (ja) ピラゾロピリミジン誘導体及びその使用
EP4349833A1 (en) Pyridazinone compound as parp7 inhibitor
KR20220127900A (ko) Jak 키나아제 관련 질병의 치료를 위한 약물의 제조에 있어서 jak 억제제의 용도
JP2025526728A (ja) 抗菌化合物
WO2015027963A1 (zh) 芳环类衍生物、其药物组合物及其应用
KR102754529B1 (ko) Pd-l1 면역조절제인 플루오로 비닐 벤즈아미드 화합물
CN116234551A (zh) 一类1,7-萘啶类化合物及其应用
KR20220053637A (ko) 치환된 우레아 다이하이드로오로테이트 탈수소효소 억제제
KR102921812B1 (ko) 피리딘 유도체 및 이의 용도
JP7663605B2 (ja) ピリミジン系三環式化合物及びその使用
CN113874379B (zh) 作为Cdc7抑制剂的四并环类化合物
JP2022501391A (ja) 細菌感染症の治療及び予防のための、置換ピリドインドール
TW202330534A (zh) 吡唑並環化合物及其應用
JP2025530793A (ja) Egfr阻害剤及びその使用